BR0213340A - Formulação de medicamento sólida para um derivado de piperazinuréia - Google Patents

Formulação de medicamento sólida para um derivado de piperazinuréia

Info

Publication number
BR0213340A
BR0213340A BR0213340-7A BR0213340A BR0213340A BR 0213340 A BR0213340 A BR 0213340A BR 0213340 A BR0213340 A BR 0213340A BR 0213340 A BR0213340 A BR 0213340A
Authority
BR
Brazil
Prior art keywords
derivative
drug formulation
piperazinurea
solid drug
methyl
Prior art date
Application number
BR0213340-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Heiko Kranz
Christoph Voelkel
Ralph Lipp
Johannes Tack
Herbert Wiesinger
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of BR0213340A publication Critical patent/BR0213340A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR0213340-7A 2001-10-18 2002-10-07 Formulação de medicamento sólida para um derivado de piperazinuréia BR0213340A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10152351A DE10152351B4 (de) 2001-10-18 2001-10-18 Feste Arzneimittelformulierung für ein Piperazinharnstoffderivat
PCT/EP2002/011229 WO2003035037A1 (de) 2001-10-18 2002-10-07 Feste arzneimittelformulierung für ein piperazinharnstoffderivat

Publications (1)

Publication Number Publication Date
BR0213340A true BR0213340A (pt) 2004-10-05

Family

ID=7703496

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0213340-7A BR0213340A (pt) 2001-10-18 2002-10-07 Formulação de medicamento sólida para um derivado de piperazinuréia

Country Status (23)

Country Link
EP (1) EP1435917A1 (cg-RX-API-DMAC7.html)
JP (1) JP2005506365A (cg-RX-API-DMAC7.html)
KR (1) KR20040047920A (cg-RX-API-DMAC7.html)
CN (1) CN1571660A (cg-RX-API-DMAC7.html)
AR (1) AR037111A1 (cg-RX-API-DMAC7.html)
AU (1) AU2002333896B2 (cg-RX-API-DMAC7.html)
BR (1) BR0213340A (cg-RX-API-DMAC7.html)
CA (1) CA2463951A1 (cg-RX-API-DMAC7.html)
CO (1) CO5580740A2 (cg-RX-API-DMAC7.html)
DE (1) DE10152351B4 (cg-RX-API-DMAC7.html)
EC (1) ECSP045108A (cg-RX-API-DMAC7.html)
HR (1) HRP20040435A2 (cg-RX-API-DMAC7.html)
IL (1) IL161166A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04003522A (cg-RX-API-DMAC7.html)
NO (1) NO20042022L (cg-RX-API-DMAC7.html)
NZ (1) NZ532287A (cg-RX-API-DMAC7.html)
PE (1) PE20030472A1 (cg-RX-API-DMAC7.html)
PL (1) PL367987A1 (cg-RX-API-DMAC7.html)
RS (1) RS32204A (cg-RX-API-DMAC7.html)
RU (1) RU2311172C2 (cg-RX-API-DMAC7.html)
UY (1) UY27500A1 (cg-RX-API-DMAC7.html)
WO (1) WO2003035037A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200403781B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3909056B2 (ja) 2001-06-27 2007-04-25 スミスクライン ビーチャム コーポレーション ジペプチジルペプチダーゼ阻害剤としてのフルオロピロリジン類
EP1749519A1 (de) * 2005-08-05 2007-02-07 Schering Aktiengesellschaft Arzneiform mit Retardtierter pH-unabhängiger Wirkstofffreisetzung für Wirkstoffe mit starker pH-abhängiger Löslichkeit
AU2007242077B2 (en) * 2006-04-26 2013-11-14 Alphapharm Pty Ltd Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
KR101654582B1 (ko) 2016-05-12 2016-09-06 그린로드(주) 원뿔형 부유 고분자 필터, 및 그의 제조장치 및 제조방법, 및 그를 포함하는 수처리 필터
RU2729223C1 (ru) * 2020-05-13 2020-08-05 Мераб Георгиевич Чикобава Дозированная форма для амплификации нуклеиновых кислот

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1246383B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per il mascheramento del sapore di farmaci
FR2668945B1 (fr) * 1990-11-12 1993-02-19 Theramex Nouveau procede de cristallisation des substances organiques et les composes ainsi obtenus.
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6207665B1 (en) * 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
ATE337307T1 (de) * 1998-02-05 2006-09-15 Pfizer Prod Inc Neue dihydroxyhexansäurederivate
EP1027885B1 (en) * 1999-02-09 2008-07-09 Pfizer Products Inc. Basic drug compositions with enhanced bioavailability

Also Published As

Publication number Publication date
DE10152351B4 (de) 2005-09-22
CN1571660A (zh) 2005-01-26
MXPA04003522A (es) 2004-07-23
AU2002333896B2 (en) 2007-07-26
NO20042022L (no) 2004-05-14
AR037111A1 (es) 2004-10-20
PE20030472A1 (es) 2003-06-16
PL367987A1 (en) 2005-03-21
AU2002333896A2 (en) 2003-05-06
RU2004115328A (ru) 2005-06-10
EP1435917A1 (de) 2004-07-14
CA2463951A1 (en) 2003-05-01
HRP20040435A2 (en) 2005-06-30
RU2311172C2 (ru) 2007-11-27
JP2005506365A (ja) 2005-03-03
DE10152351A1 (de) 2003-05-08
WO2003035037A1 (de) 2003-05-01
KR20040047920A (ko) 2004-06-05
UY27500A1 (es) 2003-06-30
NZ532287A (en) 2007-04-27
RS32204A (sr) 2006-10-27
CO5580740A2 (es) 2005-11-30
IL161166A0 (en) 2004-08-31
ECSP045108A (es) 2004-06-28
ZA200403781B (en) 2004-11-29

Similar Documents

Publication Publication Date Title
BRPI0416602A (pt) promotores da apoptose de n-acilsulfonamida
PT1033981E (pt) Formulacoes e metodos para reduzir a toxicidade de agentes antineoplasicos
YU68199A (sh) Farmaceutske formulacije koje sadrže vorikonazol
BR9909565A (pt) Derivados bicìclicos do ácido hidroxâmico
DK0509317T3 (da) Lægemidler imod knoglesygdomme
DK1123120T3 (da) Medicinsk aerosolformulering
BR0208678A (pt) Composto, composição farmacêutica, uso de um composto
CY1110600T1 (el) Αναλογα της βιταμινης d
DE60334773D1 (de) Formulierungen zur oralen verabreichung von wirkstoffen
ATE395071T1 (de) Pharmazeutische zubereitungen zur angiogenese- therapie
HUP0100539A2 (hu) D-vitamint és kálciumot tartalmazó gyógyászati készítmények és eljárás azok előállítására
BRPI0415053B8 (pt) inibidor de glicoproteína-p, método para preparar o mesmo e composição farmacêutica que compreende o mesmo
TR200101633T2 (tr) Farmasötik bileşim
BR0113590A (pt) 7-oxo-piridopirimidinas
DE69716469D1 (de) Pharmazeutische zusammensetzung enthaltend ein osteogenese foerderndes mittel und ein polyethylen-glycol
BRPI0410623A (pt) composto, processo para preparação de um composto, composição farmacêutica, e, utilização de um composto
ATE476995T1 (de) Epothilone enthaltende kombinationen und deren pharmazeutische verwendungen
BR0315659A (pt) Composição farmacêutica oral para administração uma vez ao dia para a liberação controlada de tramadol ou um sal do mesmo
HUP0004900A2 (hu) Mozgászavarok kezelésére szolgáló, hatóanyagként NMDA-receptor antagonista hatású piperidinszármazékokat tartalmazó gyógyszerkészítmények
ATE13488T1 (de) Gallium-chlorid, ein neues antikrebsmittel.
MXPA05010783A (es) Derivados antimicrobianos de [3.1.0] biciclohexilfenil-oxazolidinona y analogos.
ES2176330T3 (es) Compuestos y composiciones para administracion por inhalacion oral o insuflacion.
ECSP045108A (es) Formulación sólida para utilizar como medicamento a base de un derivado de piperazinurea
BR0011845A (pt) Complexo farmacêutico
DE60101370D1 (de) Pharmazeutische zusammensetzungen, die terbinafin enthalten

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2060 DE 29/06/2010.